CLOs on the Move

Eden Village Retirement Ctr

www.edenvillage.org

 
Eden Village Retirement Ctr is a Glen Carbon, IL-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Oneida Healthcare Center

Oneida Healthcare Center is one of the leading companies in Healthcare, Pharmaceuticals, & Biotech industry. Oneida Healthcare Center is based in Oneida, NY. You can find more information on Oneida Healthcare Center at www.oneidahealthcare.org

Elizabethtown Community Hospital

For over 75 years, Elizabethtown Community Hospital has been dedicated to meeting the healthcare needs of the community it serves. When you make a gift to the Hospital you are investing in the health and wellbeing of your community.

Montgomery General Hospital

Montgomery General Hospital is one of the leading companies in Healthcare, Pharmaceuticals, & Biotech industry. Montgomery General Hospital is based in Olney, MD. You can find more information on Montgomery General Hospital at www.montgomerygeneral.com

Ameriplan USA

How to make money Ameriplan and save on dental, vision, and prescription

Kymera Therapeutics

Kymera is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system. Kymera’s proprietary targeted protein degradation platform, called Pegasus, enables us to discover highly selective small molecule protein degraders with activity against disease-causing proteins throughout the body. We believe that our small molecule protein degraders have significant advantages over existing therapies and allow us to address a large portion of the human genome that was previously intractable with traditional modalities. Kymera focuses on biological pathways that have been clinically validated but where key biological nodes/proteins have not been drugged or have been inadequately drugged. To date, we have utilized our Pegasus platform to design novel protein degraders focused in the areas of immunology-inflammation and oncology, and continue to apply our platform’s capabilities to additional therapeutic areas.